Author

Thomas Gießmann

Observed names: Giessmann, Thomas, Gießmann, Thomas, T GIESSMANN, T Giessmann, T. GIESSMANN, T. Giessmann, T. Gießmann, Thomas Giessmann

Observed institutions: Boehringer Ingelheim (Germany), University of Bonn, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsmedizin Greifswald, Christian-Albrechts-Universität zu Kiel, Universität Greifswald, Martin Luther University Halle-Wittenberg

OpenAlex ID: A5111976152

Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging

2005 · C. SCHILLER, C.‐P. FRÖHLICH, et al. · Alimentary Pharmacology & Therapeutics · 601

PDF

The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol

2002 · Werner Siegmund, Karen Ludwig, et al. · Clinical Pharmacology & Therapeutics · 200

Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans

2004 · T GIESSMANN, K MAY, et al. · Clinical Pharmacology & Therapeutics · 168

Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses

2008 · Grzegorz Garbacz, Ralph-Steven Wedemeyer, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 162

Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well‐being and cognitive performance in hypothyroidism

2004 · W. Siegmund, K. Spieker, et al. · Clinical Endocrinology · 152

CYP2D6genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects

2004 · Thomas Giessmann, Christiane Modess, et al. · Clinical Pharmacology & Therapeutics · 129

Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans

2006 · S OSWALD, S HAENISCH, et al. · Clinical Pharmacology & Therapeutics · 106

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1

2008 · Stefan Oswald, Jörg König, et al. · Pharmacogenetics and Genomics · 101

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

2016 · P Stopfer, T Giessmann, et al. · Clinical Pharmacology & Therapeutics · 80

PDF

The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen

2005 · Werner Weitschies, Annika Bernsdorf, et al. · Pharmaceutical Research · 70

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

2014 · Sven Wind, Thomas Giessmann, et al. · Clinical Drug Investigation · 63

Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine

2020 · Sabrina T. Wiebe, Thomas Giessmann, et al. · Clinical Pharmacokinetics · 52

PDF

Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins

2006 · S OSWALD, T GIESSMANN, et al. · Clinical Pharmacology & Therapeutics · 48

Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions

2018 · Peter Stopfer, Thomas Giessmann, et al. · British Journal of Clinical Pharmacology · 47

PDF

Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms

2006 · Annika Bernsdorf, Thomas Giessmann, et al. · British Journal of Clinical Pharmacology · 45

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail

2017 · Peter Stopfer, Thomas Giessmann, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 34

PDF

Cut Edges and Surface Characteristics Produced by Different Microkeratomes

2000 · Frank W Wilhelm, Thomas Giessmann, et al. · Journal of Refractive Surgery · 30

Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research

2022 · Stefan Senekowitsch, Philipp Schick, et al. · Pharmaceutics · 25

PDF

Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults

2011 · Christian Friedrich, Andreas Port, et al. · Clinical Drug Investigation · 25

A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects

2011 · Ulrike Graefe-Mody, Thomas Giessmann, et al. · Clinical Therapeutics · 23

The Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide

2007 · Robert Hermann, Werner Siegmund, et al. · The Journal of Clinical Pharmacology · 21

Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects

2006 · T.D. Bethke, T. Giessmann, et al. · International Journal of Clinical Pharmacology and Therapeutics · 21

Disposition and Antimuscarinic Effects of the Urinary Bladder Spasmolytics Propiverine: Influence of Dosage Forms and Circadian‐Time Rhythms

2008 · Karen May, Kristin Westphal, et al. · The Journal of Clinical Pharmacology · 16

Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination

2008 · Karen May, Thomas Giessmann, et al. · European Journal of Clinical Pharmacology · 13

Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects

2012 · Christian Müller, Jörn Lötsch, et al. · European Journal of Clinical Pharmacology · 7

Works count: 48

Citation count: 2,272

H-index: 21

I10-index: 24